Navigation Links
More stringent evaluation on the use of generic medications in thoracic transplantation
Date:6/2/2009

Philadelphia, 2 June 2009 A closer look at regulatory and clinical concerns with generic immunosuppression medications in thoracic transplantation is required, according to an educational advisory by the International Society for Heart and Lung Transplantation (ISHLT) in the July 2009 issue of The Journal of Heart and Lung Transplantation (www.jhltonline.org/), published by Elsevier.

Thoracic transplant patients require immunosuppressant medications that are classified by regulating agencies around the world as "critical dose drugs" due to an increase in risk of harm from comparatively small differences in dose or concentration. These "critical dose drugs", however, do not receive any additional testing or evaluation in transplanted patients before being approved by worldwide regulating agencies.

Approval for brand names drugs is only given after careful testing by regulatory agencies. These drugs are studied in a stringently controlled format in patients who have the condition for which the drug is to be prescribed. The process for generic drug approval is different. Generic drugs are required to have the identical active ingredients as the brand product in the same strength and rate and extent of absorption. These products are then tested on a small number of healthy volunteers.

Evaluating healthy volunteers does not adequately represent the challenges faced in prescribing immunosuppressant medication in transplant recipients. Many times, transplant recipients are far from healthy and face the challenges of chronic disease, effects of drug therapy on non-translated organs, and interacting medications.

"A presumably bioequivalent generic product when applied in the setting of transplantation often demonstrates a different and unanticipated pharmacokinetic profile. This issue is of special concern in patients prone to graft rejection and especially in children", said Dr. Patricia A. Uber, Assistant Professor of Medicine at University of Maryland School of Medicine and the lead author of this advisory.

The ISHLT Board of Directors assigned a group of transplant practitioners from various countries to develop this educational advisory to inform transplant practitioners about generic immunosuppression.

Key recommendations in the educational advisory include:

  1. Education of the patient to inform the health care professionals caring for them if their immunosuppressant medication has been changed

  2. Education of other prescribers of the concerns regarding a switch to a generic immunosuppressant

  3. Awareness that heightened surveillance following a change in critical medication to avoid adverse effects such as toxicity or rejection

  4. Advocacy surrounding notification of an automatic generic substitution from the dispensing agencies to the prescriber


'/>"/>

Contact: Maureen Hunter
m.hunter@elsevier.com
215-239-3671
Elsevier
Source:Eurekalert

Related medicine news :

1. RecordGone.com Helps California Nurses Expunge Criminal Records to Meet More Stringent Licensing Standards
2. International Committee Recommends Stringent Guidelines for Translating Stem Cell Therapies From the Lab Bench to the Bedside
3. QLT announces positive results from the evaluation of Visudyne(R) combination therapy
4. Prospective Evaluation Finds High Levels of Satisfaction with ConvaTec Moldable Skin Barrier
5. Pennsylvania DEP Releases Evaluation of Air Quality Program
6. Bradmer provides clinical trial update and announces evaluation of strategic alternatives
7. Charleston Conducts Evaluation of an Opioid Symptoms Questionnaire
8. Womens cancer outcomes improved by surgical evaluation
9. CASA* Evaluation of Welfare Demonstration Program in New Jersey Finds Effective Approach to Addiction Recovery and Employment
10. New Williamsburg Health Evaluation Center, The Ultimate Investment In Future Health And Well-Being, Set To Open In March
11. Childrens cancer group recommends global evaluation system for neuroblastoma to improve treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... Michael Vick ... and transforming the quarterback position. The former overall number one pick in the 2001 ... football career. He holds the record for the most career rushing yards by a ...
(Date:4/24/2017)... ... April 24, 2017 , ... The bar for just about everything—apparel, eyewear, cars ... rarified air of pop and film stardom.(1) Not to be left out is that ... Grins now run the gamut from being encrusted with jewels and precious metals to, ...
(Date:4/24/2017)... ... ... The John P. McGovern Museum of Health and Medical Science is now ... health, and share results with their physicians. Members and guests can sign up for ... BrainCheck founder, Dr. David Eagleman, formerly at Baylor College of Medicine and now at ...
(Date:4/24/2017)... TEXAS (PRWEB) , ... April 24, 2017 , ... ... (SaaS) based healthcare compliance and credentialing solutions, today announced that Kyle Allain has ... leads symplr’s Cactus Provider Management sales and operations, including provider, payor and managed ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... ... health of individuals with HIV because it is not known to have significant ... have favorable effects to both lower cholesterol levels and dampen inflammation in the ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 2017 Companion animal ... in pets such as canine, avian and feline. ... types such as Attenuated Live Vaccines, Conjugate Vaccines, ... and Recombinant Vaccines. Attenuated live vaccines are derived ... which have been weakend under laboratory conditions. Conjugate ...
(Date:4/18/2017)... , April 18, 2017 Cogentix Medical, ... on providing the Urology, Uro/Gyn and Gynecology markets with ... the first quarter ended March 31, 2017 after the ... The Company will host a conference call and ... on Tuesday, May 2, 2017 at 4:30 p.m. Eastern ...
(Date:4/18/2017)... , April 18, 2017  Socionext Inc. ... collaboration started in 2016, in which Socionext extracts ... SOINN". The companies achieved initial results in reading ... by Artificial Brain SOINN. The results will be ... Sight, April 19-21, at booths 4505 & 4507. ...
Breaking Medicine Technology: